Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Spero Therapeutics's pretax income for the
three
months ended in Jun. 2026 was MXN-166.7 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was MXN140.3 Mil.
Spero Therapeutics's pretax margin was %.
During the past 11 years, Spero Therapeutics's highest Pretax Margin was 26.26%. The lowest was -30341.09%. And the median was -250.28%.
During the past 11 years, Spero Therapeutics's highest Pretax Margin was 26.26%. The lowest was -30341.09%. And the median was -250.28%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics Pre-Tax Income Related Terms
Spero Therapeutics Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Spero Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Spero Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spero Therapeutics Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN140.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics (MEX:SPRO) has a Pre-Tax Income of MXN140.3 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Spero Therapeutics and its competitors.
Is Spero Therapeutics' Pre-Tax Income too high?
Spero Therapeutics' current Pre-Tax Income is MXN140.3 Mil. Overall, Spero Therapeutics has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spero Therapeutics' Pre-Tax Income compare to ?
Spero Therapeutics' Pre-Tax Income of MXN140.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Spero Therapeutics and its competitors. Spero Therapeutics's current Pre-Tax Income is MXN140.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spero Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Spero Therapeutics (MEX:SPRO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN13.54, compared to a current price of MXN20.74 — trading 53.2% above its estimated fair value. The current Pre-Tax Income is MXN140.3 Mil. Spero Therapeutics' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Spero Therapeutics (MEX:SPRO), the current Pre-Tax Income is MXN140.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spero Therapeutics (MEX:SPRO) Overvalued in 2026?
Based on GuruFocus' analysis, Spero Therapeutics stock appears to be overvalued.
The current stock price of MXN20.74 is trading 53.2% above its estimated GF Value™ of MXN13.54.
GuruFocus considers Spero Therapeutics to be Significantly Overvalued.
Key valuation signals for MEX:SPRO:
Pre-Tax Income: MXN140.3 Mil
GF Value™: MXN13.54 vs. price of MXN20.74 (53.2% above fair value)
No single metric tells the full story. See the MEX:SPRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
40GF Score
Get the complete analysis for MEX:SPRO
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SPRO has been successfully added to your 
